{
  "meta": {
    "title": "66_Monoclonal_Antibodies",
    "url": "https://brainandscalpel.vercel.app/66-monoclonal-antibodies-d0bc3e68.html",
    "scrapedAt": "2025-11-30T12:34:41.893Z"
  },
  "questions": [
    {
      "text": "Cetuximab is approved for use in which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Palliation in head and neck cancer"
        },
        {
          "id": 2,
          "text": "Anal canal carcinoma"
        },
        {
          "id": 3,
          "text": "Gastric carcinoma"
        },
        {
          "id": 4,
          "text": "Lung carcinoma"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Cetuximab</strong> is used for <strong>palliation</strong> in <strong>head</strong> and <strong>neck cancer.</strong></p>\n<p><strong>Indications</strong> for use of cetuximab are:</p>\n<ul>\n<li><strong>Advanced squamous cell carcinoma</strong> of the <strong>head</strong> and<strong> neck</strong> in&nbsp;combination with radiotherapy for locally or regionally&nbsp;</li>\n<li><strong>Metastatic colorectal</strong> cancer</li>\n</ul>\n<p>Cetuximab is a recombinant chimeric monoclonal antibody against the external domain of the epidermal growth factor receptor (EGFR).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2487",
      "difficulty": "medium"
    },
    {
      "text": "A patient diagnosed with metastatic colorectal carcinoma is being treated with panitumumab. This drug acts against which of the following receptors?",
      "choices": [
        {
          "id": 1,
          "text": "PDGFR"
        },
        {
          "id": 2,
          "text": "EGFR"
        },
        {
          "id": 3,
          "text": "HER2/neu receptor"
        },
        {
          "id": 4,
          "text": "VEGF receptor"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Panitumumab</strong> is a recombinant fully-humanized <strong>monoclonal antibody</strong> that binds specifically to the external domain of the epidermal growth factor receptor (<strong>EGFR</strong>).<strong>&nbsp;</strong></p>\n<p>It is approved for use in patients with <strong>metastatic colorectal carcinoma</strong>.</p><hr><h3>Related Pearl: Monoclonal antibodies nomenclature</h3><p>Murine - <strong>0%</strong> human: &ldquo;<strong>omab</strong>&rdquo; (Tositumomab)</p>\n<p>Chimeric - <strong>65%</strong> human: &ldquo;<strong>ximab</strong>&rdquo; (Rituximab)</p>\n<p>Humanized - <strong>95%</strong> human: &ldquo;<strong>zumab</strong>&rdquo; (Trastuzumab)</p>\n<p>Fully human - <strong>100%</strong> human: &ldquo;<strong>umab</strong>&rdquo; (Adalimumab)</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2488",
      "difficulty": "medium"
    },
    {
      "text": "A 57-year-old woman is diagnosed with HER 2/neu positive breast cancer. Which of the following monoclonal antibodies is indicated for the management of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Panitumumab"
        },
        {
          "id": 2,
          "text": "Cetuximab"
        },
        {
          "id": 3,
          "text": "Trastuzumab"
        },
        {
          "id": 4,
          "text": "Bevacizumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Trastuzumab</strong> is indicated for <strong>adjuvant</strong> therapy in early and metastatic <strong>HER2 positive breast cancer</strong>.&nbsp;</p>\n<p>Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of HER2/Neu.</p>\n<div class=\"page\" title=\"Page 1213\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Human epidermal growth factor receptor 2 tyrosine kinase receptor (<strong>HER-2-TK</strong>) <strong>inhibitors</strong> are:</p>\n<ul>\n<li>Lapatinib</li>\n<li>Neratinib</li>\n</ul>\n<p><strong>Anti-Her-2 monoclonal antibodies</strong> are:</p>\n<ul>\n<li>Trastuzumab</li>\n<li>Pertuzumab</li>\n</ul>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2489",
      "difficulty": "easy"
    },
    {
      "text": "A 57-year-old woman diagnosed with breast carcinoma was prescribed trastuzumab. Which of the following statements regarding this drug is true?",
      "choices": [
        {
          "id": 1,
          "text": "It is an antibody produced entirely from mouse containing no human component"
        },
        {
          "id": 2,
          "text": "It is a monoclonal antibody produced by injecting HER-2 antigen"
        },
        {
          "id": 3,
          "text": "It is a polyclonal antibody"
        },
        {
          "id": 4,
          "text": "It is a monoclonal antibody containing only human component"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Trastuzumab</strong> is a <strong>humanized monoclonal antibody</strong> against the external domain of <strong>HER2/neu.</strong> In humanized antibodies, all components are identical to human antibodies (95% human component), except the complementary region of the variable chain that <strong>contains sequences</strong> from<strong> other species</strong>.</p>\n<p>It&nbsp;is indicated in the management of <strong>adjuvant therapy</strong> in <strong>early</strong> and <strong>metastatic HER-2 positive breast cancer.</strong>&nbsp;</p>\n<div class=\"page\" title=\"Page 1213\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Human epidermal growth factor receptor 2 tyrosine kinase receptor (<strong>HER-2-TK</strong>) <strong>inhibitors</strong> are:</p>\n<ul>\n<li>Lapatinib</li>\n<li>Neratinib</li>\n</ul>\n<p><strong>Anti-Her-2 monoclonal antibodies</strong> are:</p>\n<ul>\n<li>Trastuzumab</li>\n<li>Pertuzumab</li>\n</ul>\n</div>\n</div>\n</div>\n</div><p>The FDA recently approved <strong>tucatinib</strong> (kinase inhibitor) in combination with trastuzumab and capecitabine for the treatment of advanced unresectable breast cancer and metastatic HER-2 positive breast cancer including brain metastasis.</p><hr><h3>Related Pearl: Monoclonal antibodies nomenclature</h3><p>Murine - <strong>0%</strong> human: &ldquo;<strong>omab</strong>&rdquo; (Tositumomab)</p>\n<p>Chimeric - <strong>65%</strong> human: &ldquo;<strong>ximab</strong>&rdquo; (Rituximab)</p>\n<p>Humanized - <strong>95%</strong> human: &ldquo;<strong>zumab</strong>&rdquo; (Trastuzumab)</p>\n<p>Fully human - <strong>100%</strong> human: &ldquo;<strong>umab</strong>&rdquo; (Adalimumab)</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2490",
      "difficulty": "easy"
    },
    {
      "text": "A patient was diagnosed with HER2/neu positive breast cancer and was started on adjuvant therapy with trastuzumab. Which of the following is the most serious and dose-limiting toxicity of this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Nephrotoxicity"
        },
        {
          "id": 2,
          "text": "Neurotoxicity"
        },
        {
          "id": 3,
          "text": "Cardiotoxicity"
        },
        {
          "id": 4,
          "text": "Ototoxicity"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The most serious <strong>toxicity</strong> of <strong>trastuzumab</strong> is <strong>cardiac failure</strong>. Cardiac failure is a <strong>potentially disabling</strong> or <strong>fatal</strong> side effect unless recognized early and the drug is discontinued.</p>\n<p>Cardiotoxicity is caused by the interruption of HER2/4 heterodimer signaling in cardiomyocytes, which is a type of signaling that is essential for the maintenance of contractile function.</p>\n<p>Clinical correlation:</p>\n<ul>\n<li>Baseline <strong>ECG</strong> and cardiac<strong> ejection fraction</strong> should be <strong>monitored</strong> to rule out underlying heart disease</li>\n<li>Careful <strong>clinical follow-up</strong> for signs and symptoms of CHF</li>\n</ul>\n<p>Other side effects include&nbsp;fever, chills, nausea, dyspnea, and rashes.</p>\n<p>Dose-limiting toxicities are side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2491",
      "difficulty": "medium"
    },
    {
      "text": "A patient diagnosed with wet age-related macular degeneration is being administered ranibizumab intravitreally. All of the following are known side effects of the drug, except _______.",
      "choices": [
        {
          "id": 1,
          "text": "Eye pain"
        },
        {
          "id": 2,
          "text": "Fall in IOP"
        },
        {
          "id": 3,
          "text": "Conjunctival hemorrhage"
        },
        {
          "id": 4,
          "text": "Floaters"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Ranibizumab&nbsp;</strong>is associated with a raise in IOP, not a fall.</p>\n<p><strong>Ranibizumab</strong> is a&nbsp;monoclonal antibody directed against VEGF-A (vascular endothelial growth factor-A).&nbsp;Ranibizumab is indicated in<strong> wet age-related macular degeneration </strong>and is used<strong> intravitreally </strong>where it<strong> inhibits VEGF-A induced ocular neovascularization.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ec6b8af55d8d4214adecf78d326084bex1280x1399.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2493",
      "difficulty": "easy"
    },
    {
      "text": "Which among the following is the monoclonal antibody that is targeted specifically against VEGFR?",
      "choices": [
        {
          "id": 1,
          "text": "Bevacizumab"
        },
        {
          "id": 2,
          "text": "Ranibizumab"
        },
        {
          "id": 3,
          "text": "Ramucirumab"
        },
        {
          "id": 4,
          "text": "Aflibercept"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Ramucirumab</strong> is a monoclonal antibody that binds to <strong>VEGFR-2</strong> and inhibits the binding of VEGFR ligands.&nbsp;It is indicated in <strong>NSCLC, gastric</strong> cancer and <strong>metastatic colorectal</strong> cancer.&nbsp;</p>\n<p>Bevacizumab, aflibercept and ranibizumab are monoclonal antibodies against VEGF ligands and not the receptor.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4327",
      "difficulty": "hard"
    },
    {
      "text": "Rituximab is not used in which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Non-Hodgkin lymphoma"
        },
        {
          "id": 2,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        },
        {
          "id": 3,
          "text": "Rheumatoid arthritis"
        },
        {
          "id": 4,
          "text": "Systemic lupus ertythematosis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Rituximab</strong> is used in all conditions, except paroxysmal nocturnal hemoglobinuria.</p>\n<p><strong>Indications</strong> for <strong>rituximab</strong> include: (mnemonic- CANT MIS Ritu):</p>\n<ul>\n<li><strong>C</strong>LL</li>\n<li><strong>A</strong>utoimmune hemolytic anemia</li>\n<li><strong>N</strong>on-Hodgkin lymphoma</li>\n<li><strong>T</strong>TP</li>\n<li><strong>M</strong>arginal zone lymphomas, mantle cell lymphoma, myasthenia gravis</li>\n<li><strong>I</strong>TP</li>\n<li><strong>S</strong>LE</li>\n<li><strong>R</strong>heumatoid arthritis</li>\n</ul>\n<p>It is a <strong>chimeric monoclonal antibody</strong> targeted against the<strong> CD20 receptor</strong>&nbsp;that is present on the<strong> surface of B lymphocytes.</strong></p>\n<p>Ofatumumab and obinutuzumab are the other monoclonal antibodies directed against CD20 receptors.&nbsp;They are also approved for use in CLL.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2500",
      "difficulty": "medium"
    },
    {
      "text": "A 70-year-old man is found to have leukocytosis on his yearly health check-up.  Further evaluation led to a diagnosis of chronic lymphocytic leukemia. Immunophenotyping was positive for CD52. Which is the monoclonal antibody indicated in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Rituximab"
        },
        {
          "id": 2,
          "text": "Alemtuzumab"
        },
        {
          "id": 3,
          "text": "Cetuximab"
        },
        {
          "id": 4,
          "text": "Obinutuzumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Alemtuzumab</strong> is a humanized <strong>monoclonal antibody against CD52</strong> that is indicated in the management of <strong>chronic lymphocytic leukemia</strong> (CLL).</p>\n<p>Rituximab and obinutuzumab are monoclonal antibodies against CD20 that are also indicated in the treatment of chronic lymphocytic leukemia.</p>\n<p>Cetuximab is a chimeric&nbsp;human-mouse anti-epidermal growth factor receptor monoclonal antibody against the extracellular domain of EGFR.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2501",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following monoclonal antibodies is not a HER1 inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Pertuzumab"
        },
        {
          "id": 2,
          "text": "Cetuximab"
        },
        {
          "id": 3,
          "text": "Necitumumab"
        },
        {
          "id": 4,
          "text": "Panitumumab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Pertuzumab</strong> is a monoclonal antibody against the&nbsp;<strong>HER2 receptor.</strong>&nbsp;</p>\n<p>Pertuzumab is indicated in HER2-positive<strong>&nbsp;breast cancer</strong> in combination with trastuzumab and docetaxel.&nbsp;</p>\n<p>Monoclonal <strong>antibodies against EGFR</strong> (<strong>HER1</strong>) are:</p>\n<ul>\n<li>Panitumumab</li>\n<li>Cetuximab</li>\n<li>Necitumumab</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4321",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is a monoclonal antibody directed against PDGFR-alpha?",
      "choices": [
        {
          "id": 1,
          "text": "Panitumumab"
        },
        {
          "id": 2,
          "text": "Pertuzumab"
        },
        {
          "id": 3,
          "text": "Cetuximab"
        },
        {
          "id": 4,
          "text": "Olaratumab"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Olaratumab</strong> is a monoclonal antibody against <strong>PDGFR-alpha</strong> and blocks ligand-mediated receptor activation.&nbsp;It is indicated along <strong>with doxorubicin</strong> for adult patients with <strong>soft tissue sarcoma.</strong>&nbsp;</p>\n<p>Panitumumab and cetuximab are monoclonal antibodies against EGFR (HER1).&nbsp;</p>\n<p>Pertuzumab is a monoclonal antibody against HER2.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4322",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a bispecific monoclonal antibody?",
      "choices": [
        {
          "id": 1,
          "text": "Daratumumab"
        },
        {
          "id": 2,
          "text": "Alemtuzumab"
        },
        {
          "id": 3,
          "text": "Blinatumomab"
        },
        {
          "id": 4,
          "text": "Panitumumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Blinatumomab</strong> is a <strong>bispecific monoclonal antibody.</strong>&nbsp;</p>\n<p>Bispecific monoclonal antibody <strong>simultaneously</strong> binds to <strong>two different types</strong> of&nbsp;<strong>antigen.</strong> It&nbsp;binds simultaneously to <strong>CD3 on T cells</strong> and to <strong>CD19 on B cells</strong>. This links the two cells and activates T cells to exert cytotoxic activity against CD19 B cells.&nbsp;</p>\n<p>Blinatumomab&nbsp;is approved for the treatment of Philadelphia chromosome-negative&nbsp;relapsed or refractory B-cell precursor ALL<strong>.&nbsp;</strong></p>\n<p>Option A: Daratumumab is a monoclonal antibody against CD-38.&nbsp;</p>\n<p>Option B: Alemtuzumab is a monoclonal antibody against CD-52.&nbsp;</p>\n<p>Option D: Panitumumab is a monoclonal antibody against EGFR.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4331",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old man who presented with fever, night sweats and weight loss was evaluated and diagnosed with diffuse large B-cell lymphoma. Which of the following is a radioimmunoconjugate that can be used in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Gemtuzumab ozogamicin"
        },
        {
          "id": 2,
          "text": "Brentuximab vedotin"
        },
        {
          "id": 3,
          "text": "Denileukin deftitox"
        },
        {
          "id": 4,
          "text": "Ibritumomab tiuxetan"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Ibritumomab tiuxetan</strong> is a <strong>radioimmunoconjugate</strong> that&nbsp;is approved for use in non-Hodgkin's lymphoma. <strong>Diffuse large B-cell lymphoma</strong>&nbsp;is a subtype of <strong>non-Hodgkin's lymphoma.</strong></p>\n<p>Ibritumomab is a monoclonal antibody against CD20 which is attached to the radioactive isotope yttrium-90 using the chelator tiuxetan. Beta emission from Y-90 destroys the surrounding tissues.&nbsp;</p>\n<p>Radioimmunoconjugates provide targeted delivery of radionuclides to tumor cells. It&nbsp;is made by attaching a radioactive molecule to a monoclonal antibody.&nbsp;</p>\n<p>Option A: Gemtuzumab ozogamicin is a monoclonal antibody against CD33 covalently linked to a semisynthetic derivative of calicheamicin which is a potent antitumor antibiotic.&nbsp;</p>\n<p>Option B: Brentuximab vedotin is a monoclonal antibody against CD30 linked with microtubule disrupting agent MMAE.&nbsp;</p>\n<p>Option C: Denileukin diftitox is an immunotoxin produced by genetic recombination of IL-2 and the catalytically active fragment of diphtheria toxin.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4336",
      "difficulty": "hard"
    },
    {
      "text": "What is basiliximab?",
      "choices": [
        {
          "id": 1,
          "text": "IL-1 receptor antagonist"
        },
        {
          "id": 2,
          "text": "Anti-CD3 antibody"
        },
        {
          "id": 3,
          "text": "IL-2 receptor antagonist"
        },
        {
          "id": 4,
          "text": "TNF inhibitor"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div><strong>Basiliximab</strong>&nbsp;exhibits a high affinity towards<strong> IL-2 receptor</strong> and <strong>inhibits</strong> it. It is an anti- CD-25 monoclonal antibody.</div>\n<div>It has a short plasma half-life of 1 week. It is used to prevent transplant rejection reactions. Its adverse effects are anaphylactic reactions &amp; opportunistic infections.</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3693",
      "difficulty": "medium"
    },
    {
      "text": "A 2-year-old girl was brought to the hospital by her mother with complaints of abdominal pain and diarrhea. Examination revealed a palpable abdominal mass. Investigations showed elevated levels of urinary homovanillic acid and vanillyl mandelic acid. The lesion could not be completely resected during surgery and histopathology findings are shown in the image. Which of the following is a monoclonal antibody approved for use in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Alirocumab"
        },
        {
          "id": 2,
          "text": "Alemtuzumab"
        },
        {
          "id": 3,
          "text": "Dinutuximab"
        },
        {
          "id": 4,
          "text": "Denosumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given scenario and the histopathology (image) showing small round blue tumor cells with <strong>Homer-Wright pseudorosettes</strong>, point towards a diagnosis of paediatric<strong> neuroblastoma. D</strong><strong>inutuximab</strong> is the <strong>monoclonal antibody</strong> against glycolipid <strong>GD2</strong> which is indicated in this condition.</p>\n<p>GD2 glycolipid is expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/865333df5e6d4bc6944f21720fcf027cx1280x1096.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/da6232ea8f694e2382067f8c07e0ef17.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8265",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following drugs is recently approved for the treatment of colorectal cancer arising through Lynch Syndrome?",
      "choices": [
        {
          "id": 1,
          "text": "Ipilimumab"
        },
        {
          "id": 2,
          "text": "Nivolumab"
        },
        {
          "id": 3,
          "text": "Pembrolizumab"
        },
        {
          "id": 4,
          "text": "Atezolimumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Pembrolizumab</strong> is the drug recently approved for the treatment of <strong>colorectal cancer</strong> arising through Lynch syndrome.&nbsp;<span class=\"ILfuVd\">The increased risk for colorectal cancer in Lynch Syndrome is due to inherited <strong>mutations</strong> that impair <strong>DNA mismatch repair.</strong></span></p>\n<p>Immune checkpoint inhibitors inhibit proteins that help to keep immune responses to cancer cells in check. When these proteins are blocked, the brake on the immune system is released and T cells are able to kill cancer cells more efficiently.</p>\n<p>Pembrolizumab is an <strong>immune checkpoint inhibitor</strong>. It is a humanized monoclonal IgG4-<span class=\"ILfuVd\">&kappa; isotype antibody that blocks the interaction between programmed cell death protein (PD-1) and its ligands.</span></p>\n<p>The FDA has approved pembrolizumab for patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus&nbsp;and head and neck squamous cell cancer in combination with platin agents and 5-FU for the first-line treatment.</p><p>The FDA recently approved pembrolizumab for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5918",
      "difficulty": "medium"
    },
    {
      "text": "Pembrolizumab is not approved for use in which of the following malignancies?",
      "choices": [
        {
          "id": 1,
          "text": "Non-metastatic small cell lung cancer"
        },
        {
          "id": 2,
          "text": "Metastatic squamous cell lung cancer"
        },
        {
          "id": 3,
          "text": "Refractory classical hodgkin’s lymphoma"
        },
        {
          "id": 4,
          "text": "Urothelial cancer"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Pembrolizumab</strong> is <strong>not</strong> approved for use in <strong>non-metastatic</strong> small-cell lung cancer. It is <strong>approved</strong> for <strong>metastatic</strong> small cell lung cancer (SCLC).</p>\n<p>Pembrolizumab is a monoclonal antibody (IgG4) against PD-1 and blocks interaction between PD-1 and its ligands PD-L1 and PD-L2. It is used in the following conditions:</p>\n<ul>\n<li><strong>Metastatic SCLC </strong></li>\n<li><strong>Hodgkin’s lymphoma</strong></li>\n<li>Metastatic <strong>urothelial cancer</strong></li>\n<li><strong>Metastatic non SCLC</strong></li>\n<li>Merkel cell carcinoma</li>\n<li>Chemotherapy-refractory head and neck cancers</li>\n<li>Refractory melanoma</li>\n<li>Triple-Negative Breast Cancer</li>\n<li>Esophageal Cancer</li>\n<li>Colorectal cancer due to Lynch syndrome</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7211",
      "difficulty": "hard"
    },
    {
      "text": "Which among the following is the Interleukin-5 antagonist indicated in the management of asthma?",
      "choices": [
        {
          "id": 1,
          "text": "Omalizumab"
        },
        {
          "id": 2,
          "text": "Lebrikizumab"
        },
        {
          "id": 3,
          "text": "Reslizumab"
        },
        {
          "id": 4,
          "text": "Atezolimumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Reslizumab</strong> is a monoclonal antibody <strong>against interleukin-5</strong> that is approved for use in <strong>severe</strong>&nbsp;<strong>asthma.</strong></p>\n<p>Option A &amp; B: Omalizumab is an anti-IgE antibody and lebrikizumab is an antibody against interleukin 13, which are also indicated in the management of asthma.</p>\n<p>Option D: Atezolizumab is an immune checkpoint modulator that inhibits the interaction of PD-L1 with PD-1 and B7-H1. It is approved for use in metastatic urothelial cancer and for NSCLC.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8250",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is the monoclonal antibody developed against Bacillus anthracis?",
      "choices": [
        {
          "id": 1,
          "text": "Alemtuzumab"
        },
        {
          "id": 2,
          "text": "Omalizumab"
        },
        {
          "id": 3,
          "text": "Obiltoxaximab"
        },
        {
          "id": 4,
          "text": "Abciximab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Obiltoxaximab</strong> is a monoclonal antibody <strong>against</strong> the protective antigen of<strong> <em>Bacillus anthracis</em>.</strong></p>\n<p>It is indicated in the <strong>treatment</strong> of <strong>inhalational anthrax</strong> due to <em>B. anthracis</em> in combination with appropriate antibacterial drugs. It is also indicated for <strong>prophylaxis</strong> of inhalational anthrax.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8255",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is an immune checkpoint inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Alemtuzumab"
        },
        {
          "id": 2,
          "text": "Denosumab"
        },
        {
          "id": 3,
          "text": "Durvalumab"
        },
        {
          "id": 4,
          "text": "Abciximab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Durvalumab&nbsp;</strong>is an immune checkpoint inhibitor. It is an <strong>antagonist of PD-L1</strong> which is a protein-ligand that is present on antigen-presenting cells, T cells, B cells, and some cancer cells.</p>\n<p><strong>Immune checkpoint inhibitors</strong> inhibit proteins that help the cancer cells evade the immune response. When these proteins are blocked, the brake on the immune system is released and T cells are able to kill cancer cells more efficiently.</p>\n<p>Durvalumab is approved for use in&nbsp;<strong>metastatic urothelial</strong> and <strong>Merkel cell cancer</strong>.&nbsp;The FDA approved Durvalumab in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with <strong>extensive-stage small-cell lung cancer</strong>.</p>\n<p>Other PD-L1 inhibitors include:</p>\n<ul>\n<li>Atezolizumab</li>\n<li>Avelumab</li>\n<li>Durvalumab</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8232",
      "difficulty": "medium"
    },
    {
      "text": "A patient with rheumatoid arthritis has inadequate disease control with methotrexate. Which Janus kinase inhibitor can you add to his treatment regimen?",
      "choices": [
        {
          "id": 1,
          "text": "Ruxolitinib"
        },
        {
          "id": 2,
          "text": "Baricitinib"
        },
        {
          "id": 3,
          "text": "Dasatinib"
        },
        {
          "id": 4,
          "text": "Ponatinib"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Baricitinib</strong> is a<strong> Janus kinase inhibitor</strong> approved for use in <strong>rheumatoid arthritis</strong>.&nbsp;</p>\n<p>Oral Janus kinase inhibitors for rheumatoid arthritis are:</p>\n<ul>\n<li>Baricitinib&nbsp;</li>\n<li>Tofacitinib&nbsp;</li>\n</ul>\n<p>Option A: <strong>Ruxolitinib</strong> is a <strong>Janus kinase inhibitor</strong> approved for use in various forms of <strong>myelofibrosis</strong>, <strong>polycythemia vera</strong> and acute graft vs host disease.</p>\n<p>Options C and D: Dasatinib and ponatinib are <strong>BCR-ABL tyrosine kinase inhibitors</strong> indicated for CML.&nbsp;</p><p>In November 2020,&nbsp;the U.S. FDA issued an&nbsp;emergency use authorization (EUA)&nbsp;for baricitinib in combination with remdesivir, for the treatment of suspected or lab-confirmed COVID-19 in hospitalized adults and children two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4351",
      "difficulty": "medium"
    },
    {
      "text": "A patient has presented to the OPD with raised erythematous plaques on his arms and torso covered in silvery scales. You decide to prescribe a monoclonal antibody targeting interleukin-23 for treatment. Identify this drug.",
      "choices": [
        {
          "id": 1,
          "text": "Secukinumab"
        },
        {
          "id": 2,
          "text": "Ixekizumab"
        },
        {
          "id": 3,
          "text": "Brodalumab"
        },
        {
          "id": 4,
          "text": "Tildrakizumab"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The scenario described in the question points towards a diagnosis of<strong> chronic plaque psoriasis. Tildrakizumab</strong> is a monoclonal antibody directed <strong>against&nbsp;IL-23 </strong>used in the treatment of this condition<strong>.</strong></p>\n<p>IL-23 is&nbsp;a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab prevents the interaction of IL-23 with its receptors. It&nbsp;is indicated in moderate-to-severe plaque psoriasis.</p>\n<p><strong>Secukinumab, ixekizumab, brodalumab</strong> are other monoclonal antibodies directed against <strong>IL-17A</strong> and indicated in moderate-to-severe plaque psoriasis.</p>\n<p>Note: <strong>Ustekinumab</strong> is a monoclonal antibody against <strong>both IL-12 and IL-23</strong>. It is used for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4357",
      "difficulty": "hard"
    },
    {
      "text": "Dupilumab is indicated in the management of _______.",
      "choices": [
        {
          "id": 1,
          "text": "Resistant osteoporosis"
        },
        {
          "id": 2,
          "text": "Moderate atopic dermatitis"
        },
        {
          "id": 3,
          "text": "Guttate psoriasis"
        },
        {
          "id": 4,
          "text": "Severe rheumatoid arthritis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Dupilumab </strong>is indicated in the treatment of <strong>moderate</strong>-to-severe<strong> atopic dermatitis.&nbsp;</strong></p>\n<p>Dupilumab <strong>inhibits</strong> interleukins<strong> IL-4</strong> and <strong>IL-13</strong>. When these interleukins are inhibited, they are unable to form complexes with their receptors. This results in a decrease in the immune response&nbsp;including the release of proinflammatory cytokines, chemokines, and IgE.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4369",
      "difficulty": "medium"
    }
  ]
}